The Readout Loud

346 Odcinki

1. 304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama

   Opublikowany: 2.05.2024
2. 303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc

   Opublikowany: 18.04.2024
3. 302: Vertex's big deal, biotech's red numbers, & an industry history lesson

   Opublikowany: 11.04.2024
4. 301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

   Opublikowany: 4.04.2024
5. 300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech

   Opublikowany: 28.03.2024
6. 299: Live! From the STAT Breakthrough Summit East

   Opublikowany: 21.03.2024
7. 298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard

   Opublikowany: 14.03.2024
8. 297: VC turmoil, GLP-1 competition, & the war on recovery

   Opublikowany: 7.03.2024
9. 296: Legal insider trading, booming biotech stocks, & the next GLP-1

   Opublikowany: 29.02.2024
10. 295: Humira’s legacy, CEO symbolism, and genomic surgery

    Opublikowany: 22.02.2024
11. 294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking

    Opublikowany: 15.02.2024
12. 293: AI in medicine, detangling hype, and Icelandic DNA

    Opublikowany: 8.02.2024
13. 292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon

    Opublikowany: 1.02.2024
14. 291: The plight of the VC, Gilead's latest setback, & more M&A

    Opublikowany: 25.01.2024
15. 290: Biotech layoffs, slumping stocks, and a 2024 preview

    Opublikowany: 18.01.2024
16. 289: Live! From #JPM24

    Opublikowany: 11.01.2024
17. 287: 2023 in review, CEO report cards, and a look at the year ahead

    Opublikowany: 21.12.2023
18. 286: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future

    Opublikowany: 14.12.2023
19. 285: CRISPR history, biotech struggles, & a big week for deals

    Opublikowany: 7.12.2023
20. 284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job

    Opublikowany: 30.11.2023